Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

被引：11

作者：

Abboud, Miguel R. ^{[1
]}

Cancado, Rodolfo D. ^{[2
]}

De Montalembert, Mariane ^{[3
]}

Smith, Wally R. ^{[4
]}

Rimawi, Hala ^{[5
]}

Voskaridou, Ersi ^{[6
]}

Guvenc, Birol ^{[7
]}

Keefe, Deborah ^{[8
]}

Grosch, Kai ^{[9
]}

Nassin, Michele L. ^{[8
]}

Watson, Jimmy ^{[10
]}

Yssel, Justin ^{[10
]}

Reshetnyak, Evgeniya ^{[8
]}

Adomakoh, Yvonne Dei ^{[11
]}

机构：

[1] Amer Univ Beirut, Dept Pediat & Adolescent Med, Med Ctr, Beirut, Lebanon

[2] Hosp Samaritano Sao Paulo, Dept Hematol Oncol, Sao Paulo, Brazil

[3] Necker Enfants Malades Hosp, AP HP, Dept Gen Pediat & Pediat Infect Dis, Paris, France

[4] Virginia Commonwealth Univ, Div Gen Internal Med, Dept Med, Richmond, VA USA

[5] Jordan Univ Sci & Technol, Fac Med, Irbid, Jordan

[6] Laikon Gen Hosp, Thalassaemia Ctr, Athens, Greece

[7] Cukurova Univ, Fac Med, Dept Hematol, Adana, Turkiye

[8] Novartis Pharmaceut, E Hanover, NJ USA

[9] Novartis Pharma AG, Basel, Switzerland

[10] Novartis Ireland Ltd, Global Hlth DU, Dublin, Ireland

[11] Univ Ghana, Med Sch, Korle Bu Teaching Hosp, Accra, Ghana

来源：

关键词：

D O I：

10.1182/blood-2023-185429

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4